Mounjaro vs Zepbound: What Actually Decides Which One You Get

Mounjaro or Zepbound: which should you ask for?

Start with the line that sounds like you:

• You have type 2 diabetes and commercial insurance: Mounjaro is the on-label choice. If your plan covers it, the Mounjaro Savings Card can bring it to $25.
• Your goal is weight management and you're insured: Zepbound is the on-label choice. A Mounjaro prescription written for weight loss alone won't qualify for Mounjaro's card.
• You pay cash, whatever your diagnosis: Zepbound from Lilly costs about $300 to $450 a month, against about $500 for Mounjaro. Ask whether your chart supports the Zepbound label.
• You're on Medicare: Part D can cover Mounjaro for type 2 diabetes. For weight, the GLP-1 Bridge charges $50 for the Zepbound KwikPen if you qualify.
• Your labs sit in the gray zone: a rising A1C without a diabetes diagnosis, or weight gain without a qualifying BMI. Ask your prescriber which label your chart honestly supports, since neither card approves a mismatch.

Are Mounjaro and Zepbound the same drug?

Yes. Both are tirzepatide, made by Eli Lilly, in the same six strengths from 2.5 mg to 15 mg. Both are weekly shots. The medicine in a Mounjaro pen and a Zepbound pen at the same dose is the same.

The two names exist because Lilly went through two FDA approvals for two uses. Mounjaro was approved in May 2022 for type 2 diabetes. Zepbound followed in November 2023 for weight management. In December 2024, Zepbound added moderate to severe obstructive sleep apnea in adults with obesity. For how the drug works, see what Zepbound is and how it works.

Comparing tirzepatide with a different drug instead? Semaglutide vs tirzepatide covers that, and Mounjaro vs Ozempic compares those two diabetes brands. For older drugs and supplements, see Mounjaro vs. the alternatives.

If it's the same drug, why do price and coverage differ?

Insurance pays for approved uses, not molecules. Your plan checks the diagnosis on your prescription against what the drug is FDA-labeled to treat. A plan can cover Mounjaro for type 2 diabetes and deny Zepbound for obesity, or the reverse.

That is also why the coupons don't cross over. Lilly runs a separate savings card for each brand, tied to that brand's label. A Mounjaro card won't work on a Zepbound fill.

Mounjaro vs Zepbound cost: what will each one cost you?

• Zepbound, Lilly self-pay: about $300 at 2.5 mg, about $400 at 5 mg and about $450 from 7.5 mg. The $450 price needs each refill within 45 days. Late refills cost about $500 at 7.5 mg and about $700 from 10 mg.
• Mounjaro, Lilly self-pay: about $500 a month at every dose, through LillyDirect or the savings card if your plan won't cover it.
• With insurance that covers your drug: as little as $25 a month with that brand's savings card.
• List price, no program: about $1,110 a month for Mounjaro and about $1,085 for the Zepbound single-dose pen. A GoodRx coupon barely lowers either.

So paying cash, Zepbound costs less than Mounjaro at every dose, as long as you refill on time. Late refills from 10 mg cost more than Mounjaro. Lilly's self-pay prices and both savings cards run through Dec 31, 2026. For the full picture on each brand, see Mounjaro cost and Zepbound cost.

Lilly has no free program for either brand right now. Lilly Cares, its charity for people with low incomes, does not list Mounjaro or Zepbound. It does list Trulicity, an older weekly shot for type 2 diabetes. For each brand's card and cheapest prices, see Mounjaro savings, Zepbound savings, Mounjaro cheapest and Zepbound cheapest.

Which one will your doctor prescribe, and can you ask for the other?

The diagnosis on your chart usually decides it. Type 2 diabetes points to Mounjaro. Obesity, or overweight with a weight-related condition, points to Zepbound. Some prescribers do write Mounjaro off-label for weight loss, for example when a plan covers Mounjaro but excludes Zepbound.

Many women in their 40s and 50s fall between the two. Changing hormones can push A1C into the prediabetes range and add belly fat, without either number crossing a diagnosis line. That is a reason to ask which label fits your labs, not a reason to give up.

And yes, you can ask for the other one. What changes is which card and price you can use. A clinician who treats hormones and metabolism together can help you sort it out. Midi Health is one menopause-focused option.

Does Medicare or a commercial plan cover either one?

Medicare Part D can cover Mounjaro as a diabetes drug for people with type 2 diabetes, at the plan's own copay. In 2026, Part D drug costs stop at $2,100 a year.

Medicare long could not cover drugs used only for weight loss. Since July 1, 2026, the Medicare GLP-1 Bridge lets eligible Part D members get the Zepbound KwikPen for $50 a month, through December 31, 2027. It covers the KwikPen only, has BMI and health rules, and excludes people with type 2 diabetes. It does not cover Mounjaro.

Commercial coverage varies by employer for both drugs. Prior authorization reviewers check that your diagnosis matches the label. If neither path works, see Mounjaro without insurance and Zepbound without insurance.

Is the dose schedule the same for both?

Yes. Both start at 2.5 mg for four weeks, then 5 mg. The dose can rise in 2.5 mg steps, each after at least four weeks, up to 15 mg if needed. For the full schedule, see tirzepatide dosage.

Are the side effects different?

No. Same medicine, same side effects. Nausea, diarrhea and constipation are the most common, and they tend to follow dose increases rather than the brand name. See tirzepatide side effects for what to expect.

Can you switch from Mounjaro to Zepbound, or back?

Yes. The most common reason is insurance: a plan starts covering one brand's use and not the other. A new type 2 diabetes diagnosis can also lead a prescriber to Mounjaro.

Because the doses are identical, a prescriber can switch you at your current dose. What to check is the paperwork. Each savings card and refill window is tracked by brand, so ask your pharmacist whether yours carries over.

What about compounded tirzepatide instead of either brand?

Compounded tirzepatide is made by a pharmacy for one patient. It is not FDA-approved, and it has no insurance or savings card. Month-to-month prices run from about $130 to $650 across sellers.

Since Lilly's self-pay Zepbound starts at about $300, the gap is smaller than many people expect, especially at low doses. For sellers and the legal side, see compounded tirzepatide providers and Zepbound vs. compounded tirzepatide.